TN lawmaker proposes allowing for 12-month supply of birth control in bill
NASHVILLE, Tenn. (WKRN) — A Memphis Democrat wants those buying birth control to be able to receive one year's supply in the state of Tennessee.
Sen. Raumesh Akbari has proposed SB 589, which would require all health plans, as defined in state law, to provide contraceptive coverage in 12-month refills of the drug at one time for someone insured.
According to present law, health plans that provide prescription coverage for birth control must allow for 12-month supplies unless the patient requests a smaller amount; however, present law does not require a health benefit plan to cover contraceptives provided by a doctor or at a pharmacy that does not participate in that specific plan.
Akbari's bill would change the definition of 'health benefit plan' to include a 'hospital, surgical, or medical expense policy; health, hospital or medical service corporation contract; a policy or agreement entered into by a health insurer, or a health maintenance organization contract offered by an employer; other plan administered by the state; or a certificate issued under those policies, contracts or plans.'
The bill would also prohibit any health plan that provides hormonal contraceptive coverage from imposing 'utilization controls' or other forms of 'medical management' that limit the supply of contraceptives to anything less than a 12-month supply.
Additionally, the bill revises the definition of 'contraceptive' to remove the requirement that the contraceptive be one that is 'legally marketed' by the FDA.
⏩
According to the fiscal note on the bill, estimates on how much the bill could cost up to $1.4 million starting in Fiscal Year 2026.
The effective date on the bill would be Jan. 1, 2026.
Lawmakers were set to discuss the bill in the Senate Commerce and Labor Committee on Tuesday, March 25.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
7 minutes ago
- New York Post
MSNBC host tells Colbert that Trump has started to ‘f— around with the military'
MSNBC host Nicolle Wallace said Tuesday that it felt different to have President Donald Trump 'f— around with the military' in his second term during an interview with late-night host Stephen Colbert. Wallace argued that there were no 'normal Republicans' in Trump's current administration and said 'what's different about Stephen Miller running the ICE raids, and running basically a siege of Los Angeles, is that there is no Mark Esper, Jim Mattis, and that's the big difference, and that is the danger.' Colbert then asked Wallace about the National Guard troops and the Marines that have been sent to Los Angeles to help quell the riots. 'We have seen Trump stretch his presidential powers over the last five months. Is this different?' 'It feels different, it feels different to, can we swear here?' she asked as Colbert said she could. 'To f— around with the military, it feels really different, and he wanted to the first time, but people like Mark Milley, people stopped him. It feels really different to use the military as pawns out loud and as a public tactic. That feels different to me.' A battalion of 700 U.S. Marines are mobilizing in Los Angeles to respond to anti-immigration enforcement riots, just days after Trump deployed the National Guard to the area as well. White House spokeswoman Abigail Jackson responded to criticism of Trump's actions on Tuesday, telling Fox News Digital that 'violent rioters in Los Angeles, enabled by Democrat Gov. Gavin Newsom, have attacked American law enforcement, set cars on fire, and fueled lawless chaos.' On The Late Show with Stephen Colbert, MSNBC host Nicolle Wallace said President Donald Trump 'f— around with the military' had a different feeling compared to what he has done throughout his time in office. Scott Kowalchyk/CBS 'President Trump rightfully stepped in to protect federal law enforcement officers. When Democrat leaders refuse to protect American citizens, President Trump will always step in,' she added. Colbert also asked Wallace about the state of the Democratic Party and asked the MSNBC host if they were 'in danger of an autocrat.' 'I don't know, and I think that, in politics, you are one leader away from a comeback, you're one moody character away from this unlikely hero. And so I think the Democratic Party hasn't rotted. I mean the Democratic Party has not corrupted itself, it hasn't turned on itself in the way that the Republican Party has. And I think the Democratic Party is one leader away from being something fresh and appealing to a majority of others again. I think the Republican Party is still heading down, down, down following Trump and his authoritarian ways,' she said. Wallace claims there are no 'normal Republicans' in Trump's current administration and that the difference is that with Stephen Miller running the ICE raids, it is basically running a siege in Los Angeles, California. AP Wallace previously made headlines earlier this year while covering Trump's address to Congress, during which the president made a 13-year-old cancer survivor, DJ Daniel, an honorary Secret Service agent. 'But I think this was a lesson in finding one thing that you let yourself feel,' Wallace said during her coverage of the address. 'And I let myself feel joy about DJ, and I hope he's alive for another, you know, 95 years, and I hope he lives the life he wants to live. He wants to be a cop. He knows what he wants to do, and maybe when you have childhood cancer, that crystallizes for you.' 'I hope he has a long life as a law enforcement officer,' she continued. 'But I hope he never has to defend the United States Capitol against Donald Trump's supporters, and if he does, I hope he isn't one of the six who loses his life to suicide, and I hope he isn't one who has to testify against the people who carried out acts of seditious conspiracy and then lived to see Donald Trump pardon those people.' The MSNBC host was criticized by Trump and the White House at the time.
Fox News
19 minutes ago
- Fox News
DOJ slams Newsom's 'crass political stunt' over Trump's call-up of National Guard amid LA anti-ICE riots
The Department of Justice (DOJ) argues the courts should deny California's request for a restraining order against the Trump administration over its decision to activate National Guard soldiers in Los Angeles after violent riots broke out over the weekend amid Immigration and Customs Enforcement (ICE) raids in the city. Democratic leaders in California claim President Donald Trump abused his authority by invoking a provision of Title 10 that allows the president to mobilize the National Guard if an invasion or rebellion is underway. California Gov. Gavin Newsom, a Democrat, said in a statement Monday that Trump caused the bulk of the rioting because he unnecessarily deployed the military to protect ICE personnel and federal buildings. Newsom also claimed local and state police had the situation under control when Trump spurred chaos by issuing his National Guard proclamation. Weighing in on the matter a day ahead of a scheduled hearing, the DOJ made its case that Trump had the authority to call on the National Guard's response. "In a crass political stunt endangering American lives, the Governor of California seeks to use this Court to stop the President of the United States from exercising his lawful statutory and constitutional power to ensure that federal personnel and facilities are protected," the DOJ said. "But, under the Constitution, the President is the Commander in Chief of the armed forces, and the President is responsible for ensuring the protection of federal personnel and federal facilities." Since Friday, violent rioters who object to ICE's enforcement of immigration laws have targeted and damaged federal buildings, injured federal personnel and impeded federal functions, the DOJ said. The Los Angeles Police Department (LAPD) and other state and local law enforcement officials have been unable to bring order to Los Angeles, the DOJ claimed. The agency also pointed to a comment made by LAPD Chief Jim McDonnell, who said during a news conference that "things have gotten out of control" and warned that "somebody could easily be killed." "Evaluating the unrest and threats to the enforcement of federal law that local and state authorities were unable or unwilling to control, the President responded by using the authority vested in him by statute and the Constitution to federalize and deploy the California National Guard to protect federal personnel and property, quell the mobs, and restore order," the DOJ wrote. "When the situation escalated further, the Secretary of Defense deployed a group of U.S. Marines to further assist. "The President has every right under the Constitution and by statute to call forth the National Guard and Marines to quell lawless violence directed against enforcement of federal law," the DOJ continued. "Yet instead of working to bring order to Los Angeles, California and its Governor filed a lawsuit in San Francisco seeking a court order limiting the federal government's ability to protect its property and officials." The DOJ said California's request would "countermand" the president's military directives, which would be "unprecedented." "On the merits, Plaintiffs' claims are baseless," the DOJ said. Newsom also claimed Trump never consulted with him before activating the National Guard, though the statute does not have such a requirement, the DOJ said. "It merely directs, as a procedural matter, that the President's orders be conveyed "through" the Governor," the DOJ wrote. "They were." Historically, courts did not interfere when former President Dwight Eisenhower deployed the military to protect school desegregation, nor did they interfere when former President Richard Nixon deployed the military to deliver the mail during a postal strike. Ultimately, the DOJ recommended the court deny California and Newsom's motion for a temporary restraining order or preliminary injunction. Newsom's office did not immediately respond to Fox News Digital's request for comment.
Medscape
31 minutes ago
- Medscape
Taletrectinib Approved for NSCLC
The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ROS1 tyrosine kinase inhibitor (TKI) exposure. Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib. A third ROS1 TKI approved in 2023, repotrectinib, is also a next-generation medicine. Like repotrectinib, FDA granted taletrectinib a breakthrough therapy designation. Compared with crizotinib and entrectinib, Nuvation Bio data suggests taletrectinib has greater brain penetration, lower incidence of neurologic adverse events, less likelihood of resistance, and other benefits, plus a possible safety and efficacy edge over next-generation rival repotrectinib. 'Taletrectinib will likely become the preferred treatment option for advanced ROS1+ NSCLC,' commented Thomas E. Stinchcombe, MD, an associate editor at the Journal of Clinical Oncology , in the 'Context' section of his journal's publication of a pooled analysis of Nuvation Bio's two approval studies, TRUST-I and TRUST-II, in April. Taletrectinib was originally developed in China and was approved there in Jan 2025 for the same indication granted by FDA. The company plans a US launch in mid-2025, they stated in a press release. About 2% of NSCLC patients have ROS1-positive disease, and about a third of them present with brain metastases. ROS1-positive patients have an oncogenic rearrangement in the ROS1 gene, which leads to an abnormal ROS1 fusion protein that drives cancer growth. ROS1 TKIs block the protein's activity. The drug's approval was based on results of TRUST-I and TRUST-II, phase 2, single-arm, open label studies in ROS1-positive NSCLC patients treated with oral taletrectinib 600 mg once daily until progression, unacceptable toxicity, death, or consent withdrawal. Of the 273 subjects in the pooled analysis, 93.8% had stage IV disease, 33.7% had brain metastases, and 27.1% had received chemotherapy. TRUST-I included Chinese subjects who were either new to TKIs or who had received crizotinib. TRUST-II included patients from North America, Europe, and Asia who were TKI-naive or who had been treated with crizotinib or entrectinib. The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who were naive to treatment with a ROS1 TKI and 113 patients (66 in TRUST-I; 47 in TRUST-II) who had received one prior ROS1 TKI. Patients may have received prior chemotherapy for advanced disease. For treatment-naive patients, the overall response rate (ORR) was 90% in TRUST-I and 85% in TRUST-II, with 72% and 63% of responders having a duration of response (DOR) of at least a year, respectively. For TKI-pretreated patients, ORR was 52% in TRUST-I and 62% in TRUST-II, with 74% and 83% of responders having a DOR of at least 6 months, respectively. Among 13 patients with a G2032R mutation, which triggers resistance to first generation ROS1 TKIs, eight (61.5%) had a response to taletrectinib. In a safety analysis with 352 patients, the most frequent treatment-emergent adverse events with taletrectinib were gastrointestinal problems (88%) and elevated aspartate aminotransferase (72%) and alanine aminotransferase (68%). Neurologic adverse events included dizziness (21%) and dysgeusia (15%). Overall, 33% of patients had grade 3 or higher treatment-related adverse events. Treatment-emergent adverse events led to discontinuation in 7% of patients. There were three treatment-related deaths due to abnormal hepatic function, liver failure, and pneumonia. Prescribing information for taletrectinib includes warnings and precautions for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity. The recommended taletrectinib dose is 600 mg orally once daily on an empty stomach until disease progression or unacceptable toxicity. Taletrectinib pricing was not available, but fourteen 160 mg capsules of rival repotrectinib — the initial 2-week supply with daily dosages doubling afterwards — is $7,666.97, according to
